A Study to Evaluate the Safety of Subunit Influenza Vaccine in People Aged 6 Months and Older
A Post-Marketing, Open-Label, Single-Arm Observational Study to Evaluate the Safety and Vaccination Influencing Factors of Subunit Influenza Vaccine in Individuals Aged 6 Months and Older
This is a post-marketing, prospective observational study to evaluate the safety of a subunit influenza vaccine and the factors influencing influenza vaccination in individuals aged 6 months and older. A total of 7,000 vaccinated participants will be divided into Subgroup A (1,000 participants, active surveillance) and Subgroup B (6,000 participants, passive surveillance), and monitored for adverse events and serious adverse events within 28 days after vaccination. Participants in Subgroup A will additionally complete an electronic questionnaire on their knowledge of influenza and factors influencing their vaccination decisions.
研究概览
详细说明
Study Objectives The primary objectives of this study are: (1) to evaluate the safety of the subunit influenza vaccine in individuals aged 6 months and older after vaccination, in order to assess the occurrence of adverse reactions; and (2) to investigate vaccinated individuals' knowledge of influenza and influenza vaccine, and the factors influencing their vaccination decisions.Study Design This is a post-marketing, prospective, open-label, single-arm observational study. Participants who have already received the subunit influenza vaccine at the study site will be enrolled and divided into two subgroups according to the surveillance mode: Subgroup A (1,000 participants) under active surveillance, and Subgroup B (6,000 participants) under passive surveillance. All participants will be observed for 30 minutes after vaccination and monitored for adverse events (AEs) and serious adverse events (SAEs) within 28 days after vaccination.Study Population Individuals aged 6 months and older who have received the subunit influenza vaccine at the study site and are able to comply with the study requirements. Participants with allergy to any vaccine component (including excipients, formaldehyde, or Triton N-101), acute illness, severe chronic disease, acute exacerbation of chronic disease, fever, uncontrolled epilepsy, other progressive neurological diseases, a history of Guillain-Barré syndrome, or a history of severe adverse reactions to previous influenza vaccination will be excluded.Safety Monitoring All participants will remain under observation for 30 minutes immediately after vaccination. The occurrence of AEs and SAEs within 28 days post-vaccination will be collected and recorded, including solicited local reactions (pain, swelling, erythema, pruritus, induration, ecchymosis) and systemic events (fever, cough, headache, rhinorrhea, fatigue, myalgia, arthralgia, gastrointestinal symptoms, rash, etc.). Subgroup A participants will receive a telephone follow-up on Day 28, while Subgroup B participants will self-report AEs to investigators during the same period. Any SAE will be reported in accordance with applicable regulations.Influencing Factor Survey Participants in Subgroup A will complete an electronic questionnaire during the post-vaccination observation period (by themselves if aged 18 years or older, or by their guardians if under 18), collecting demographic information, medical and vaccination history, and their knowledge of influenza and influenza vaccine, as well as the factors influencing their vaccination decisions.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:XiaoRong Zhong
- 电话号码:86-18907078306
- 邮箱:gzcdcjmk@126.com
学习地点
-
-
Jiangxi
-
Ganzhou、Jiangxi、中国
- 招聘中
- Ganzhou Center for Disease Control and Prevention (Ganzhou Health Comprehensive Supervision and Law Enforcement Bureau)
-
接触:
- XiaoRong Zhong
- 电话号码:86-18907078306
- 邮箱:gzcdcjmk@126.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Healthy individuals aged 6 months and older who have received the subunit influenza vaccine at the study site and meet the eligibility criteria.
描述
Inclusion Criteria:
- Aged 6 months and older;
- Have received the subunit influenza vaccine at the study site;
- Able to comply with the requirements of the study protocol
Exclusion Criteria:
- Allergy to any component of the vaccine, including excipients, formaldehyde, or the splitting agent Triton N-101;
- Acute illness, severe chronic disease, acute exacerbation of chronic disease, or fever;
- Uncontrolled epilepsy or other progressive neurological diseases, or a history of Guillain-Barré syndrome;
- History of severe adverse reactions following previous influenza vaccination;
- Any other condition deemed by the investigator to be unsuitable for enrollment.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Group A
Active Surveillance Group |
Participants will receive one dose of Subunit Influenza Vaccine |
|
Group B
Passive Surveillance Group |
Participants will receive one dose of Subunit Influenza Vaccine |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Occurrence of AEs and ADRs
大体时间:Within 28 days post-vaccination
|
Adverse events and adverse drug reactions occurring within 28 days of vaccination will be recorded, including solicited local and systemic reactions. |
Within 28 days post-vaccination
|
|
Occurrence of SAEs
大体时间:Within 28 days post-vaccination
|
Serious adverse events occurring within 28 days of vaccination will be recorded. |
Within 28 days post-vaccination
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.